UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
December 3, 2001
-----------------------------------------------------------
(Date of earliest event reported)
Cephalon, Inc.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19119 23-2484489
- --------------------------------- ------------- ---------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) ID No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
- ---------------------------------------- -----------
(Address of principal executive offices) (Zip Code)
(610) 344-0200
-----------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
--------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
ITEM 5. OTHER EVENTS.
On December 3, 2001, Cephalon, Inc. (the "Registrant") publicly announced an
agreement under which the Registrant will acquire the French pharmaceutical
company Group Lafon, including its commercial, R&D and manufacturing operations.
The Registrant hereby incorporates by reference the press release attached
hereto as Exhibit 99.1, and made a part of this Item 5.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED: None
(b) PRO FORMA FINANCIAL INFORMATION: None
(c) EXHIBITS: Reference is made to the Exhibit Index annexed hereto and
made a part hereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CEPHALON, INC.
Date: December 3, 2001 By: /s/ J. Kevin Buchi
------------------------
J. Kevin Buchi
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT PAGE
- ------- ----
99.1 Press Release